News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
226,791 Results
Type
Article (5026)
Company Profile (18)
Press Release (221747)
Multimedia
Podcasts (1)
Webinars (4)
Section
Business (82212)
Career Advice (461)
Deals (15045)
Drug Delivery (8)
Drug Development (19065)
Employer Resources (30)
FDA (3676)
Job Trends (3901)
News (120119)
Policy (7505)
Tag
Academia (293)
Accelerated approval (2)
Adcomms (3)
Allergies (10)
Alliances (14799)
ALS (22)
Alzheimer's disease (250)
Antibody-drug conjugate (ADC) (12)
Approvals (3699)
Artificial intelligence (49)
Autoimmune disease (5)
Automation (4)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (14)
Biotechnology (21)
Bladder cancer (13)
Brain cancer (7)
Breast cancer (52)
Cancer (528)
Cardiovascular disease (28)
Career advice (393)
Career pathing (3)
CAR-T (42)
CDC (2)
Cell therapy (118)
Cervical cancer (2)
Clinical research (16137)
Collaboration (207)
Compensation (208)
Complete response letters (2)
COVID-19 (303)
CRISPR (12)
C-suite (133)
Cystic fibrosis (17)
Data (644)
Denatured (1)
Depression (8)
Diabetes (49)
Diagnostics (2052)
Digital health (4)
Diversity, equity & inclusion (13)
Drug discovery (16)
Drug pricing (8)
Drug shortages (1)
Duchenne muscular dystrophy (15)
Earnings (41341)
Editorial (2)
Employer branding (6)
Employer resources (32)
Events (38142)
Executive appointments (358)
FDA (4037)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (219)
Gene editing (20)
Generative AI (2)
Gene therapy (57)
GLP-1 (119)
Government (415)
Guidances (93)
Healthcare (5043)
Huntington's disease (3)
IgA nephropathy (5)
Immunology and inflammation (18)
Indications (9)
Infectious disease (319)
Inflammatory bowel disease (26)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (18)
Interviews (53)
IPO (7855)
IRA (3)
Job creations (1121)
Job search strategy (360)
Kidney cancer (9)
Labor market (5)
Layoffs (100)
Leadership (5)
Legal (2334)
Liver cancer (19)
Lung cancer (62)
Lymphoma (38)
Management (10)
Manufacturing (61)
MASH (31)
Medical device (3872)
Medtech (3873)
Mergers & acquisitions (7456)
Metabolic disorders (139)
Multiple sclerosis (9)
NASH (6)
Neurodegenerative disease (14)
Neuropsychiatric disorders (1)
Neuroscience (369)
NextGen: Class of 2025 (1674)
Non-profit (728)
Now hiring (3)
Obesity (60)
Opinion (30)
Ovarian cancer (18)
Pain (15)
Pancreatic cancer (16)
Parkinson's disease (34)
Partnered (4)
Patents (28)
Patient recruitment (35)
Peanut (5)
People (24726)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase I (4819)
Phase II (7012)
Phase III (5578)
Pipeline (763)
Policy (10)
Postmarket research (625)
Preclinical (1889)
Press Release (66)
Prostate cancer (37)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (85)
Real estate (1876)
Recruiting (8)
Regulatory (5166)
Reports (17)
Research institute (302)
Resumes & cover letters (68)
Rett syndrome (8)
Schizophrenia (24)
Series A (35)
Series B (26)
Sickle cell disease (7)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (4)
Startups (1011)
Stomach cancer (1)
Supply chain (12)
Tariffs (5)
Vaccines (43)
Venture capital (3)
Weight loss (22)
Women's health (2)
Date
Last 7 days (114)
Last 30 days (504)
Last 365 days (9369)
2025 (4602)
2024 (11027)
2023 (13193)
2022 (18660)
2021 (19681)
2020 (18238)
2019 (13207)
2018 (10205)
2017 (10002)
2016 (9156)
2015 (12119)
2014 (9587)
2013 (7708)
2012 (8329)
2011 (8797)
2010 (8634)
Location
Africa (185)
Alabama (14)
Alaska (2)
Arizona (62)
Arkansas (1)
Asia (11517)
Australia (1622)
California (2313)
Canada (806)
China (86)
Colorado (98)
Connecticut (103)
Delaware (39)
Europe (24733)
Florida (348)
Georgia (40)
Idaho (24)
Illinois (124)
India (7)
Indiana (72)
Iowa (7)
Japan (93)
Kansas (24)
Kentucky (13)
Louisiana (6)
Maine (43)
Maryland (255)
Massachusetts (1861)
Michigan (88)
Minnesota (151)
Mississippi (1)
Missouri (23)
Montana (16)
Nebraska (12)
Nevada (29)
New Hampshire (16)
New Jersey (671)
New Mexico (5)
New York (547)
North Carolina (359)
North Dakota (4)
Northern California (1116)
Ohio (68)
Oklahoma (5)
Oregon (4)
Pennsylvania (402)
Puerto Rico (1)
Rhode Island (14)
South America (276)
South Carolina (10)
Southern California (830)
Tennessee (47)
Texas (279)
United States (8289)
Utah (69)
Virginia (58)
Washington D.C. (15)
Washington State (195)
West Virginia (2)
Wisconsin (27)
226,791 Results for "contrafect corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
ContraFect Corporation announces business updates and financial results for the second quarter ended June 30, 2023.
August 14, 2023
·
12 min read
Pharm Country
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
ContraFect Corporation today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston.
September 19, 2023
·
6 min read
Pharm Country
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
ContraFect Corporation today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023.
September 18, 2023
·
8 min read
Pharm Country
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
ContraFect Corporation announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.
August 28, 2023
·
5 min read
Business
ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update
ContraFect Corporation (Nasdaq: CFRX) today announces business updates and financial results for the first quarter ended March 31, 2023.
May 15, 2023
·
11 min read
Pharm Country
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
ContraFect Corporation announces that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company’s common stock.
June 27, 2023
·
4 min read
Business
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update
ContraFect Corporation(Nasdaq: CFRX) today announces business updates and financial results for the fourth quarter and full year ended December 31, 2022.
March 31, 2023
·
12 min read
Business
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
ContraFect Corporation announced financial results and business updates for the third quarter ended September 30, 2022.
November 14, 2022
·
14 min read
Pharm Country
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
ContraFect Corporation announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023.
June 8, 2023
·
6 min read
Drug Development
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyCF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial
ContraFect Corporation (Nasdaq: CFRX) today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study.
October 16, 2023
·
8 min read
1 of 22,680
Next
